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Background: Gpr151 is an orphan GPCR whose function is unknown. The restricted pattern of neuronal expres-
sion in the habenula, dorsal horn of the spinal cord and dorsal root ganglion plus homologywith the galanin fam-
ily of receptors imply a role in nociception.
Results: Real-time quantitative RT-PCR demonstrated a 49.9 ± 2.9 fold highly signiﬁcant (P b 0.001) increase in
Gpr151 mRNA expression in the dorsal root ganglion 7 days after the spared nerve injury model of neuropathic
pain. Measures of acute, inﬂammatory and neuropathic pain behaviours were not signiﬁcantly different using
separate groups of Gpr151 loss-of-function mutant mice and wild-type controls. Galanin at concentrations be-
tween 100 nM and 10 μM did not induce calcium signalling responses in ND7/23 cells transfected with Gpr151.
Conclusions:Our results indicate that despite the very large upregulation in the DRG after a nerve injurymodel of
neuropathic pain, the Gpr151 orphan receptor does not appear to be involved in the modulation of pain-related
behaviours. Further, galanin is unlikely to be an endogenous ligand for Gpr151.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Background
An increasing number of groups have used microarray analysis of
mRNA transcripts to identify the molecular changes in the dorsal root
ganglia (DRG) and spinal cord that occur after peripheral nerve injury
and in models of neuropathic pain (Costigan et al., 2002; Grifﬁn et al.,
2003). The aim of these studies is to identify genes that are up- or
down-regulated after nerve injury in the expectation that some may
be involved in the development and/or maintenance of neuropathic
pain and would thus be targets for analgesic drug development
(Costigan et al., 2002; Grifﬁn et al., 2003).
The orphan G-protein coupled receptor (GPCR) Gpr151 is amember
of the class A rhodopsin-like family and has recently been shown to be
signiﬁcantly up-regulated in the DRG following neuronal injury models
of neuropathic pain (Jiang et al., 2015; Reinhold et al., 2015). Gpr151
was originally identiﬁed as having homology to galanin receptors, and
variously designated as GPCR10, GPCR-2037, GalRL (Berthold et al.,
2003; Ignatov et al., 2004; Takeda et al., 2002) or PGR7 (Vassilatis et
al., 2003). Sequence-structure phylogenetic analysis of the rhodopsin-
like family placed Gpr151 within ‘cluster 14’, together with galanin
receptor 1 (GalR1), GalR2, GalR3 and the kisspeptin receptor (Kiss1R/
Gpr54) (Kakarala and Jamil, 2014), and comparable sequence analysis
placed Gpr151 within the wider ‘SOG’ subfamily that includes somato-
statin, opioid, galanin and kisspeptin receptors (Civelli et al., 2013),
though other reports mention an ambiguous relationship to other rho-
dopsin-like family members (Bjarnadottir et al., 2006; Gloriam et al.,
2007; Vassilatis et al., 2003).
Strong expression of Gpr151 mRNA within the brain is restricted to
the medial and lateral habenulae (Berthold et al., 2003; Ignatov et al.,
2004), and is also detected in the paraventricular nucleus of the thala-
mus ((Ignatov et al., 2004; Lein et al., 2007) http://www.brainatlas.
org). The medial habenula and lateral habenula have distinct neural
connectivity, and play roles in pain, analgesia, stress, memory, depres-
sion and nicotine withdrawal (Hikosaka, 2010; Shelton et al., 2012a),
andGpr151 is among themost enriched transcriptswithin thehabenula
(Quina et al., 2009). In the peripheral nervous system Gpr151 is
expressed in the DRG, trigeminal ganglia and vestibular ganglia
(Ignatov et al., 2004). Although the endogenous ligand for Gpr151 is un-
known, it has been suggested to share structural features with galanin
due to aweak activation by galanin (EC50 of 2 μM), but not by other pep-
tides including galanin 1–16 or galanin-like peptide (Ignatov et al.,
2004).
In this study we have focused on the expression of Gpr151 in the
DRG and demonstrated a marked increase in mRNA levels after nerve
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injury, in contrast to the decrease in expression of GalR1 and GalR2.
Comparing mice homozygous for a targeted disruption of Gpr151
(MUT) to strain-matchedwild-type (WT) controls, no signiﬁcant differ-
ences were observed in a range of pain behaviours in intact animals or
in models of inﬂammatory or neuropathic pain. Further, we show that
the receptor is not activated by galanin, consistent with its status of an
orphan receptor.
2. Results
2.1. Gpr151 mRNA is strongly induced after spared nerve injury
To test whether the expression of Gpr151 is altered in DRG after the
spared nerve injury (SNI) model of neuropathic pain, real-time quanti-
tative RT-PCR was used with expression levels normalized to Gapdh
(glyceraldehyde 3-phosphate dehydrogenase) mRNA, which is un-
changed following peripheral nerve injury (Kerr et al., 2008). Seven
days after SNI, the expression of Gpr151 mRNA increased 49.9 ± 2.9
fold compared with control (P b 0.001) in lumbar L4 and L5 DRG (Fig.
1). As the Gpr151 gene is intronless, expression levels could be compro-
mised by DNA contamination. This was not a problemwith the samples
tested as the average threshold cycle values (Ct) at which ﬂuorescence
exceeded the threshold limit in reverse transcribed (RT+) control
RNA reactions was 30.7 cycles, whereas that of non-reverse transcribed
(RT-) control RNA was N40 cycles.
Previously we have detectedmRNA expression of the galanin recep-
tors GalR1 and GalR2 in mouse DRG, whereas GalR3 expression is too
low for reliable comparison between samples (Hobson et al., 2006).
Here we show that seven days after SNI there is a decrease of approxi-
mately 20% in the expression of both GalR1 (P b 0.05) and GalR2
(P b 0.01) mRNAs (Fig. 1).
2.2. Targeted disruption of GpR151 does not alter pain-like behaviours
To investigate whether Gpr151 might play a role in the modulation
of acute pain-like behaviour we tested thermal and mechanical with-
drawal thresholds in naiveWT andGpr151MUTmice and found no sig-
niﬁcant differences between the two genotypes. Thermal withdrawal
thresholds were 8.8 ± 0.7 s and 9.9 ± 0.7 s for WT and Gpr151 MUT
mice, respectively (Fig. 2A). Mechanical 50% withdrawal thresholds
were 1.18± 0.17 g and 1.08± 0.16 g forWT and Gpr151MUTmice, re-
spectively (BL3, Fig. 2B). There was also no signiﬁcant difference in the
chronic pain-like allodynia which develops following SNI: by 3 d post-
SNI mechanical 50% withdrawal thresholds had decreased to 0.20 ±
0.09 g in the WT and 0.27 ± 0.06 g in the Gpr151 MUT (D3, Fig. 2B).
Allodynia was not signiﬁcantly different between the genotypes at any
time point over the 4 weeks following SNI (Fig. 2B). The formalin test
of acute inﬂammatory nociceptive pain showed similar pain-related be-
havioural responses in both WT and Gpr151 MUT mice over 1 h post-
formalin (Fig. 2C). The total amount of time spent in nocifensive behav-
iours in the ﬁrst 10 min (due to direct stimulation of nociceptors) was
247 ± 24 s for WT and 248 ± 26 s for Gpr151 MUT; and 351 ± 51 s
for WT and 501± 51 s for Gpr151 MUT in the second phase (due to in-
ﬂammatory mechanisms and central sensitisation in the dorsal horn of
the spinal cord), which although showing a trend towards greater pain-
like behaviour in Gpr151 MUT mice, was not statistically signiﬁcant
(P= 0.056).
2.3. Gpr151 signalling is not activated by galanin
Since Gpr151 shows homologywith the galanin receptors and a pre-
vious study had demonstrated weak activation by galanin (EC50 of
2 μM),we testedwhether galanin could induce intracellular calcium sig-
nalling via activation of Gpr151. ND7/23 cells (a hybridoma of mouse
neuroblastoma and rat DRG (Wood et al., 1990)) were transiently
transfected with Gpr151, and calcium signalling measured using the
calcium indicator Fluo-4. As shown in Fig. 3 addition of galanin at con-
centrations of 100 nM, 1 μM, 3 μM and 10 μM failed to elicit a calcium
response indicating that galanin is unlikely to be an endogenous ligand
of this orphan GPCR.
3. Discussion
Acute pain is a protective adaptive survival responsewhich avoids or
reduces potential tissue-damage until healing has occurred (Basbaum
et al., 2009; Costigan et al., 2009). In contrast, chronic pain is maladap-
tive, and is characterised by an enhanced sensitivity to noxious stimuli,
as well as pain in response to innocuous or no stimuli (spontaneous
pain) which persists beyond a useful defensive and recuperative pur-
pose. Chronic pain remains a signiﬁcant healthcare problem, is notori-
ously difﬁcult to treat and there is a huge unmet need for better and
more effective analgesic drugs (Costigan et al., 2009; Scholz and
Woolf, 2002). The mechanisms underlying the transition from acute to
chronic pain remain incompletely understood but it is apparent that
changes in both neuronal and non-neuronal cell populations contribute
Fig. 1. Gpr151 and GalR1/GalR2 mRNA expression levels are differentially affected in adult mouse DRG oneweek after SNI. In quantitative RT-PCR assays the expression of Gpr151mRNA
increased by 49.923 ± 2.907 fold compared to control (n= 4; P=0.0005), whereas GalR1 and GalR2 mRNAs respectively decreased to 0.803± 0.037 (n=4; P=0.0131) and 0.786 ±
0.019 (n= 4; P= 0.0015) of control. Data are shown as means ± SE, in which expression after SNI (ﬁlled boxes) was compared with contralateral controls of 1.00 relative units (open
boxes). Note the difference in scales between the Gpr151 and GalR1/GalR2 results. *P b 0.05; **P b 0.01; ***P b 0.001.
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to an overall maladaptive plasticity in the pain matrix (Costigan et al.,
2009) that lead to on-going pain states.
Following nerve injury there are signiﬁcant changes in the transcrip-
tional proﬁles of cells throughout the pain pathway which are thought
to contribute to the development and/or maintenance of chronic pain
(Costigan et al., 2002; Grifﬁn et al., 2003). Several groups have used a
range of techniques, which include transcriptional proﬁling and real-
time quantitative RT-PCR, to identify and then quantify changes in
gene expression in the rodent DRG and/or dorsal horn of the spinal
cord after nerve injury models of neuropathic pain (Costigan et al.,
2002; Grifﬁn et al., 2003; Jiang et al., 2015; Reinhold et al., 2015). The
data described here shows that SNI induces a very clear difference in
the mouse DRG 7 days after surgery between the marked 50-fold in-
crease in Gpr151 mRNA and the modest, though signiﬁcant, 20%
decrease in the related receptors GalR1 and GalR2. These changes are
comparable to previous reports: Reinhold described a 14.1 fold increase
in Gpr151 in mouse DRG 7 days after the chronic constriction model of
neuropathic pain (Reinhold et al., 2015) whilst Jiang described a 27.7
fold change in mouse DRG 10 days after the spared nerve ligation
model of neuropathic pain (Jiang et al., 2015). The changes in DRG
GalR1 and GalR2 mRNA expression are also comparable to previous re-
ports following complete section of the sciatic nerve (axotomy), using
in situ hybridization (Sten Shi et al., 1997; Xu et al., 1996) and quantita-
tive RT-PCR (Hobson et al., 2006). Of note, we attempted to perform im-
munocytochemistry for Gpr151 in the DRG of wildtype mice using a
number of different commercially available Gpr151 polyclonal antisera.
In all cases identical straining was observed in DRG from wildtype and
Gpr151 KOmice strongly implying the observed staining in non-specif-
ic, similar to that previously described for other GPCR peptides
receptors.
In addition to Gpr151 expression in the DRG, high levels of mRNA
and protein have been described in the habenula (Berthold et al.,
2003; Broms et al., 2015; Ignatov et al., 2004; Lein et al., 2007) which
is located in the dorsal thalamus. The habenula has been implicated in
a range of roles that include pain, analgesia, reward and motivational
processing (reviewed in (Shelton et al., 2012a; Shelton et al., 2012b))
and is thought to act in part as a relay in descending pain modulation
from the nucleus accumbens to the periaqueductal gray (Yu and Han,
1990). Further, peripheral nociceptive stimulation has been shown to
excite lateral habenula neurons in both rats and humans (Gao et al.,
1996; Shelton et al., 2012a; Shelton et al., 2012b), whilst stimulation
of the habenula produces analgesia in the formalin test (Cohen and
Melzack, 1986) which is reversed by injection of naloxone onto the
habenula (Mahieux and Benabid, 1987).
Since Gpr151: (a) expression is markedly increased in the DRG after
models of neuropathic pain; (b) is expressed in the habenula which is
modulated by nociceptive stimulation; and (c) is homologous to the
galanin receptors which are known to modulate nociception (reviewed
in (Lang et al., 2015)), we compared thermal and mechanical nocicep-
tive responses in intact Gpr151 MUT and WT mice and then in models
of inﬂammatory and neuropathic pain. No differences were observed
Fig. 2. Pain-related behaviours are unchanged in mice lacking Gpr151. A: baseline thermal withdrawal thresholds were similar in WT (open box) and Gpr151 MUT (ﬁlled box) mice. B:
withdrawal thresholds tomechanical stimulationwere tested 3 days before (BL3) and at several time points after spared nerve injury (SNI) for up to 28days. No differences in pain-related
withdrawal thresholds were observed betweenWT (n=8) and Gpr151MUTmice (n=10) at any time point. C:mice were injectedwith 20 μl 1% formalin into the plantar hind paw and
nocifensive behaviourmonitored in 5min bins for 1 h. Therewere no signiﬁcant differences in pain-related behaviour betweenWT (n=6) andGpr151MUT (n=10)mice in theﬁrst (0–
10 min) or second (10–60 min) phases of the test.
Fig. 3. Galanin does not induce calcium signalling in cells expressing Gpr151. ND7/23 cells
transfected with Gpr151 were loaded with Fluo-4, exposed to various concentrations of
galanin (0–10 μM) or ionomycin as a positive control and calcium signalling measured
by an increase in Fluo-4 intensity. RFU = relative ﬂuorescence units. No increase in
intracellular calcium was observed at any concentration of galanin in marked contrast to
ionomycin.
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in anymodality implying that the receptor does not appear to play a role
in nociception. Thereforewepropose that Gpr151 and its cognate ligand
may play a neuroprotective and/or pro-regenerative role in the DRG
after nerve injury, similar to that previously described for galanin and
activating transcription factor-3 (Hobson et al., 2006; Holmes et al.,
2003; Holmes et al., 2000; Mahoney et al., 2003; Saito and Dahlin,
2008).
The lack of a responsewith galanin using calcium imaging in ND7/23
cells (a sensory neuron-like cell line) transiently transfected with
Gpr151 contradicts, in part, the previous published work by Ignatov
(Ignatov et al., 2004). In that paper non-neuronal CHO cells stably
transfected with the promiscuous Gα16 G-protein and apoaequorin
(to allow the use of calciummobilisation via activation of phospholipase
C and inositol trisphosphate) were then transiently transfected with
Gpr151 (designated GalRL in that paper). Of note, galanin induced a
rise in the calcium-induced bioluminescence response in the vector-
transfected cells as well as those transfected with Gpr151, implying
the effect of galanin, may in part, be non-speciﬁc. Further, the EC50 for
galanin in the Gpr151 transfected CHO cells was 2 μM which is N500-
fold higher than the reported ﬁgures for each of the three galanin recep-
tor subtypes and 20-fold higher than the top of the dose-response curve
for each receptor (reviewed in (Lang et al., 2015) and references there-
in). Taken together, our data using the ND7/23 neuronal cell and the
work of Ignatov make it unlikely that galanin is an endogenous ligand
for Gpr151. Further, it would seem counter-intuitive for the receptor
and ligand to both be very signiﬁcantly upregulated in the DRG after pe-
ripheral nerve injury since that would be likely to cause a rapid
desensitisation of any putative function(s) of the Gpr151, in marked
contrast to other neuropeptides where a reciprocal relationship in ex-
pression between ligand and receptor is often reported (Hokfelt et al.,
1994).
4. Conclusion
In summary, we found that despite the very large upregulation in
the DRG after a nerve injury model of neuropathic pain, the Gpr151 or-
phan receptor does not appear to be involved in themodulation of pain-
related behaviours. Further, galanin is unlikely to be an endogenous li-
gand for Gpr151. These ﬁndings are consistent with the hypothesis
that activation of the orphan receptor may instead play a neuroprotec-
tive and/or pro-regenerative role in the DRG after nerve injury. Further
work is now needed to test the Gpr151 MUT mice in a range of in vitro
and in vivo functional and anatomical assays of neuroprotection and re-
generation compared to WT controls. However, it is only when the en-
dogenous ligand for the Gpr151 has been identiﬁed and characterised
that conﬁrmation of these putative roles will be possible.
5. Materials and methods
5.1. Animals and genotyping
All animals were housed in groups of 2–4 in a 14:10 h light/dark
cycle (lights on at 7:00 am) and an ambient temperature of 22 ± 2 °C.
Mice had access to standard chow and water ad libitum. Procedures
were carried out in accordance with the U.K. Animals (Scientiﬁc Proce-
dures) Act 1986 and associated guidelines.
To study changes in nociception andmRNAexpression after SNI, 11–
14 week old male 129/OlaHsd mice (Bristol University colony) were
anesthetized, and the common peroneal and sural branches of the
right sciatic nerve were sectioned leaving the tibial branch intact
(Holmes et al., 2008). 7 days later mice were killed by cervical disloca-
tion to obtain ipsilateral (SNI) and contralateral (control) lumbar L4
and L5 DRG pools each from 8 to 12 animals (n= 4). Tissues were fro-
zen on dry ice and stored at−80 °C.
Heterozygousmicewith one targeted allele of Gpr151were generat-
ed by Deltagen Inc. and obtained from the Jackson Laboratory (stock
number 005805; strain B6.129P2-Gpr151tm1Dgen/J, i.e. targetedmutation
1, Deltagen), in which a portion of the Gpr151 coding region (nt 155–
271 of NM_181543) was replaced by a SA-IRES-LacZ-Neo cassette,
resulting in an allele with β-galactosidase expression under the control
of the endogenous Gpr151 promoter and targeted disruption of the
Gpr151 (Gpr151 MUT). All experiments were performed using 10–
12 week old animals bred to homozygosity for the targeted allele and
strain-, age- and sex-matched WT controls. Animals were genotyped
by PCR with three primers:
Construct forward 5′-CTGGATCTCGAGTGATCAGGTACC-3′,
Gpr151 forward 5′- CCTAAACAAGAAGCTACCATCTGCA-3′,
Gpr151 reverse 5′-AGTCAGAGGACTTGCAGATGAACC-3′.
Cycling conditions were 95 °C for 7 mins; 40 cycles of 94 °C for
30 s/62 °C for 30 s/72 °C for 90 s; and a ﬁnal 72 °C incubation for
10 min, resulting in ampliﬁed products of 178 and 395 bp from
Gpr151 MUT and WT alleles, respectively.
5.2. Real-time quantitative RT-PCR assays
Total RNA isolation, DNase treatment and re-extraction, and
reverse transcription (RT) reactions with random hexamers were as
published (Kerr et al., 2004). Real-time RT-PCR assays and the endoge-
nous control glyceraldehyde 3-phosphate dehydrogenase (Gapdh),
GalR1 and GalR2 primer and probe sets were as reported (Hobson et
al., 2006), except for the corrected GalR2 probe sequence 5′-
TTCCTCACTATGCACGCCAGCAGC-3′ (mGalR2-46TAQ) used then and
herein. TheGpr151 primer and probe setwasdesigned using default pa-
rameters of Primer Express software (Applied Biosystems):
Forward primer 5′-GGGAACACGAAGGCCAAGA-3′,
Reverse primer 5′-AGTGGTACAAGTAAACACAGTAACGACAA-3′,
Non-extendable Taqman probe 5′-
CTCAAGTCTGTTAATTGCAGCCCTCTGT-3′,
corresponding, respectively, to nucleotides (nt) 1273–1291, 1366–
1338 and 1320–1293 of the reference RNA (NM_181543). The Gpr151
probe had a 5′ ﬂuorescent reporter dye FAM (6-carboxy-ﬂuorescein)
and the 3′ quencher dye TAMRA (6-carboxy-tetramethyl-rhodamine),
and assay primer and probe concentrationswere optimized against par-
tial-length Gpr151 cDNA cloned from mouse DRG (nt 982–1555 of
NM_181543). All primers and probe sets were synthesized by Applied
Biosystems. Relative mRNA expression levels were derived by the com-
parative threshold cycle (Ct) method, with results presented asmean of
log transformed data and statistical signiﬁcance judged by two-tailed
paired t-test, as previously described (Kerr et al., 2008). Each assay am-
pliﬁed a single product of the expected size, as detected by gel electro-
phoresis on 4% agarose gel (data not shown).
5.3. Pain-related behaviours
Mice were habituated to the testing chambers for 3 days for 30 min
prior to testing. Paw thermal withdrawal thresholds were measured
using a Hargreaves apparatus (Ugo Basile). Three measurements were
taken for each hind paw. Paw withdrawal thresholds to mechanical
stimuli were determined using Von Frey hairs employing the ‘up-
down’ testing method as previously described (Holmes et al., 2003).
To determine inﬂammatory nociceptive responses the formalin test
(Hobson et al., 2006) was used. 20 μl of 1% formalin was injected subcu-
taneously into the right hind paw and time spent in nocifensive behav-
iours (licking, biting, shaking, lifting of the paw) were measured in
5 min periods over 1 h.
For all tests the experimenter was blind to the mouse genotype.
5.4. Calcium ﬂux assay
ND7/23 cells (ECACC 92090903, (Wood et al., 1990)) were tran-
siently transfected with a Gpr151 plasmid (OriGene, USA) using Lipo-
fectamine 2000 according to the manufacturer's instructions
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(Invitrogen), and maintained in normal culture medium overnight
(high glucose DMEM with L-glutamine, supplemented with 10% FBS
and 1% Pen/Strep, Sigma, UK) before being re-plated into dark walled
96 well plates (at a density of 7000 cells per well, resulting in 50–200
cells per ﬁeld during the experiment). At the start of the imaging exper-
iment, cells were washed once before loading with 2.5 μM Fluo-4 Ca2+
indicator (Invitrogen) and 0.5 μM Hoechst nuclear stain in phenol red-
free DMEM including 10% FBS, 100 U/ml penicillin, 0.1 mg/ml strepto-
mycin and 25 mM HEPES (Sigma, UK), then incubated at 37 °C for
30 min. After loading the sample plate into IN Cell Analyzer System
(GE Healthcare) and live cell populations imaged using ×10 objective
magniﬁcation and various concentrations of porcine galanin (Bachem,
UK) were added to experimental wells. Image analysis including
localisation and quantiﬁcation of ﬂuorescence intensity, using the
multi-target analysis algorithm was performed using IN Cell Analyzer
work station 3.5 software (IN Cell Investigator, GE Healthcare). Green
channel (Fluo-4) and blue channel (Hoechst) images were used to de-
ﬁne whole-cell and nuclear regions, respectively. For graphical repre-
sentation and statistical analysis the average Fluo-4 intracellular
intensity (population-averaged) was calculated and standardised
against the resting intracellular ﬂuorescent intensity and expressed as
relative ﬂuorescence units (RFU).
5.5. Statistical analyses
Data are presented as the mean ± SEM. Quantitative real time RT-
PCR data, baseline thermal withdrawal thresholds and cumulative for-
malin test data were analysed by Student's t-test. Mechanical with-
drawal thresholds and formalin test data were analysed by two way
repeated measures ANOVA. Results were taken to be signiﬁcant if
P b 0.05.
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